• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Miromatrix Medical Inc. (Amendment)

    2/14/24 5:00:01 PM ET
    $MIRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MIRO alert in real time by email
    SC 13G/A 1 miromatrixmedicalinc13ga.htm SC 13G/A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)*

    Miromatrix Medical Inc.
    (Name of Issuer)
    Common Stock, par value $0.00001 per share
    (Title of Class of Securities)
    60471P108
    (CUSIP Number)
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
    Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:
    ☐Rule 13d-1(b)
    ☑Rule 13d-1(c)
    ☐Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Continued on following pages
    Page 1 of 8 Pages
    Exhibit Index: Page 7
    1

    SCHEDULE 13G
    CUSIP: 60471P108                                        Page 2 of 8 Pages

    1.
    Names of Reporting Persons

    Cheshire MD Holdings, LLC
    2.
    Check The Appropriate Box if a Member of a Group (See Instructions)
    (a) ☐
    (b) ☐
    3.SEC Use Only
    4.
    Citizenship or Place of Organization

    Delaware
    Number of
    Shares
    Beneficially
    Owned By
    Each
    Reporting
    Person
    With
    5.
    Sole Voting Power
    0
    6.
    Shared Voting Power
    0
    7.
    Sole Dispositive Power
    0
    8.
    Shared Dispositive Power
    0
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
    0
    10.Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares
    ☐
    11.
    Percent of Class Represented By Amount in Row (9)
    0%
    12.
    Type of Reporting Person (See Instructions)
    OO










    (1) See Item 4 below. This constitutes an exit filing for the Reporting Person.
    2

    SCHEDULE 13G
    CUSIP: 60471P108                                        Page 3 of 8 Pages

    1.
    Names of Reporting Persons

     DaVita Inc.
    2.
    Check The Appropriate Box if a Member of a Group (See Instructions)
    (a) ☐
    (b) ☐
    3.SEC Use Only
    4.
    Citizenship or Place of Organization

    Delaware
    Number of
    Shares
    Beneficially
    Owned By
    Each
    Reporting
    Person
    With
    5.
    Sole Voting Power
    0
    6.
    Shared Voting Power
    0
    7.
    Sole Dispositive Power
    0
    8.
    Shared Dispositive Power
    0
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
    0
    10.Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares
    ☐
    11.
    Percent of Class Represented By Amount in Row (9)
    0%
    12.
    Type of Reporting Person (See Instructions)
    CO, HC













    (1) See Item 4 below. This constitutes an exit filing for the Reporting Person.
    3

    SCHEDULE 13G
    Page 4 of 8 Pages

    Explanatory Note: This Amendment is being filed to report that the Reporting Persons have ceased to be the beneficial owners of more than five percent of the outstanding shares of common stock of the “Issuer”. This Amendment constitutes an exit filing for the Reporting Persons.
    Item 1(a)
    Name of Issuer

    Miromatrix Medical Inc.
    Item 1(b)
    Address of the Issuer’s Principal Executive Offices

    6455 Flying Cloud Drive, Suite 107
    Eden Prairie, MN 55344
    Item 2(a)
    Names of Persons Filing
    This statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):
    (i)Cheshire MD Holdings, LLC (“Cheshire”), and
    (ii)DaVita Inc. (“DaVita”)

    This statement relates to shares of Common Stock (as defined herein) held directly by Cheshire. As a result of DaVita’s ownership interest in Cheshire, DaVita may be deemed to indirectly beneficially own the shares of Common Stock directly beneficially owned by Cheshire.
    Item 2(b)
    Address of the Principal Business Office, or if none, Residence
    c/o DaVita Inc.
    2000 16th Street
    Denver, CO 80202
    Item 2(c)
    Citizenship
    (i)Cheshire is a Delaware limited liability company
    (ii)DaVita is a Delaware corporation
    Item 2(d)
    Title of Class of Securities
    Common Stock, par value $0.00001 per share (“Common Stock”)
    Item 2(e)
    CUSIP Number
    60471P108
    Item 3
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

    Not Applicable
    Item 4Ownership
    Item 4(a)
    Amount Beneficially Owned:

    As of December 31, 2023, the Reporting Persons did not beneficially own any shares of the Issuer’s Common Stock. Accordingly this Schedule 13G/A constitutes an exit filing for the Reporting Persons.
    Item 4(b)
    Percent of Class:

    As of December 31, 2023, each of the Reporting Persons may be deemed the beneficial owner of 0.0% of the shares of Common Stock outstanding.
    4

    SCHEDULE 13G
    Page 5 of 8 Pages

    Item 4(c)
    Number of Shares as to which such person has:

    (i) Sole power to vote or direct the vote: 0

    (ii) Shared power to vote or direct the vote: 0

    (iii) Sole power to dispose or direct the disposition of: 0

    (iv) Shared power to dispose or direct the disposition of: 0
    Item 5
    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following ☒.
    Item 6
    Ownership of More than Five Percent on Behalf of Another Person
    Not Applicable.
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
    Not Applicable.
    Item 8
    Identification and Classification of Members of the Group
    Not Applicable.
    Item 9
    Notice of Dissolution of Group
    Not Applicable.
    Item 10
    Certification
    Not Applicable.
    5

    SCHEDULE 13G
    Page 6 of 8 Pages

    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Date: February 14, 2024

    CHESHIRE MD HOLDINGS, LLC
    By:/s/ Steve Phillips
    Name:Steve Phillips
    Title:Vice President
    DAVITA INC.
    By:/s/ Stephanie Berberich
    Name:Stephanie Berberich
    Title:Assistant Secretary
    6

    SCHEDULE 13G
    Page 7 of 8 Pages

    EXHIBIT INDEX

    Ex.Page No.

    A
    Joint Filing Agreement8




    7

    SCHEDULE 13G
    Page 8 of 8 Pages

    EXHIBIT A
    JOINT FILING AGREEMENT
    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the shares of Common Stock, par value $0.00001 per share, of Miromatrix Medical Inc., and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.
    The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.
    This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.
    IN WITNESS WHEREOF, the undersigned have executed this Agreement as of February 14, 2024.

    CHESHIRE MD HOLDINGS, LLC
    By:/s/ Steve Phillips
    Name:Steve Phillips
    Title:Vice President
    DAVITA INC.
    By:/s/ Stephanie Berberich
    Name:Stephanie Berberich
    Title:Assistant Secretary
    8
    Get the next $MIRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MIRO

    DatePrice TargetRatingAnalyst
    7/19/2021$22.00Buy
    Craig Hallum
    More analyst ratings

    $MIRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger

      United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. ("Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. The tender offer expired at one minute after 11:59 p.m., New York City time, on Decem

      12/13/23 9:15:00 AM ET
      $MIRO
      $UTHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • United Therapeutics and Miromatrix Medical Announce Successful Tender Offer

      United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. ("Merger Sub"), a wholly owned subsidiary of United Therapeutics, to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. The tender offer expired at one minute after 11:59 p.m., New York City time, on December 11, 2023. Contine

      12/12/23 6:00:00 AM ET
      $MIRO
      $UTHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Miromatrix Reports Third Quarter 2023 Results

      EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results. Due to the Company's pending proposed transaction with United Therapeutics Corporation (NASDAQ:UTHR) ("United Therapeutics"), the Company's management has suspended guidance for 2023 and will not hold a conference call to discuss third quarter 2023 results. Third Quarter 2023 Financial Results Unrestricted cash and investments totaled $16.1 million as of September 30, 2023, compared to

      11/14/23 4:05:00 PM ET
      $MIRO
      $UTHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MIRO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Miromatrix Medical Inc.

      15-12G - Miromatrix Medical Inc. (0001527096) (Filer)

      12/26/23 6:02:20 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Miromatrix Medical Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update

      8-K - Miromatrix Medical Inc. (0001527096) (Filer)

      12/18/23 4:30:50 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Miromatrix Medical Inc.

      EFFECT - Miromatrix Medical Inc. (0001527096) (Filer)

      12/18/23 12:15:26 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MIRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider United Therapeutics Corp claimed ownership of 27,419,228 shares (SEC Form 3)

      3 - Miromatrix Medical Inc. (0001527096) (Issuer)

      12/14/23 2:06:09 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Heine Lisa Wipperman returned 67,413 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Miromatrix Medical Inc. (0001527096) (Issuer)

      12/13/23 4:51:18 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Maag Peter returned 58,368 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Miromatrix Medical Inc. (0001527096) (Issuer)

      12/13/23 4:50:50 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MIRO
    Leadership Updates

    Live Leadership Updates

    See more
    • ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer

      DENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2022 Preliminary Results and Other Data (Unaudited)Received nine new orders for MRIdian systems totaling approximately $56 million, compared to seven new orders totaling approximately $41 million in the fourth quarter of 2021. A total of 32 orders were received for the twelve months ended December 31, 2022, compared to 28 orders for the twelve months ended December 31, 2021. Total backlog i

      1/9/23 6:00:00 AM ET
      $AXGN
      $MIRO
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Miromatrix Appoints Jack Lake, M.D., as Medical Director

      EDEN PRAIRIE, Minn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced today that it has appointed Jack Lake, M.D. as the Company's new Medical Director. Dr. Lake is a Professor of Surgery and Medicine and the Chief of Hepatology in the Department of Medicine at the University of Minnesota. He is also the Executive Medical Director for Solid Organ Transplantation at the University of Minnesota Medical Center. Dr. Lake will serve as Miromatrix's Medical Director while remaining in his current roles at the Universit

      8/10/22 7:00:00 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Miromatrix Names Jim Douglas as New Chief Financial Officer

      EDEN PRAIRIE, Minn., March 01, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced the appointment of Jim Douglas as the Company's new Chief Financial Officer (CFO) effective March 1, 2022. As CFO, Jim will lead Miromatrix's finance organization and oversee all financial activities of the corporation. Mr. Douglas will succeed Brian Niebur, who will continue to serve Miromatrix as the Vice President of Finance. "On behalf of everyone at Miromatrix and our Board of Directors, I want to thank Brian for his many contributions duri

      3/1/22 5:15:00 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MIRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Miromatrix Medical with a new price target

      Craig Hallum initiated coverage of Miromatrix Medical with a rating of Buy and set a new price target of $22.00

      7/19/21 8:16:42 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MIRO
    Financials

    Live finance-specific insights

    See more
    • Miromatrix Reports Third Quarter 2023 Results

      EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results. Due to the Company's pending proposed transaction with United Therapeutics Corporation (NASDAQ:UTHR) ("United Therapeutics"), the Company's management has suspended guidance for 2023 and will not hold a conference call to discuss third quarter 2023 results. Third Quarter 2023 Financial Results Unrestricted cash and investments totaled $16.1 million as of September 30, 2023, compared to

      11/14/23 4:05:00 PM ET
      $MIRO
      $UTHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Update

      EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2023 financial results and provided a corporate update. "Miromatrix remains on pace to submit a response to the FDA's clinical hold letter relating to our miroliverELAPtm IND application in the second half of 2023," said Jeff Ross, Ph.D., Miromatrix CEO. "We continue to progress towards our goal of gaining authorization from the FDA to initiate a Phase 1 clinical trial to treat patients suffering from acute liver failure and

      8/14/23 4:01:00 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Miromatrix to Report Second Quarter 2023 Financial Results

      EDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the second quarter 2023 after market close on Monday, August 14, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Individuals interested in listening to the conference call may do so by dialing 866-652-5200 for domestic callers or 412-317-6060 for international callers. Please reference Conference ID: 10181369. To l

      7/25/23 4:01:00 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MIRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Miromatrix Medical Inc. (Amendment)

      SC 13G/A - Miromatrix Medical Inc. (0001527096) (Subject)

      2/14/24 5:00:01 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Miromatrix Medical Inc. (Amendment)

      SC 13G/A - Miromatrix Medical Inc. (0001527096) (Subject)

      2/14/24 1:59:27 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Miromatrix Medical Inc.

      SC 13D - Miromatrix Medical Inc. (0001527096) (Subject)

      12/22/23 9:51:15 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care